Acute Myeloid Leukemia Medical Services in China

Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy characterized by the rapid proliferation and accumulation of abnormal, immature myeloid progenitor cells—blasts—in the bone marrow and peripheral blood. These malignant blasts impair normal hematopoiesis, leading to cytopenias (anemia, neutropenia, thrombocytopenia) and systemic consequences including infection, bleeding, and organ infiltration. AML arises from acquired somatic mutations in hematopoietic stem or progenitor cells, commonly involving genes such as FLT3, NPM1, CEBPA, IDH1/2, DNMT3A, and TP53. Pathogenesis involves a stepwise accumulation of genetic and epigenetic alterations that confer survival advantage, blocked differentiation, and uncontrolled self-renewal. Clonal evolution and microenvironmental dysregulation further contribute to treatment resistance and relapse. Epidemiologically, AML accounts for approximately 80% of acute leukemias in adults and has an annual incidence of 3–5 cases per 100,000 people in Western populations; incidence rises sharply after age 60, with median diagnosis age at 68 years. In China, age-standardized incidence is slightly lower (2.1–2.7 per 100,000), but absolute case numbers are substantial due to population size and aging demographics. Risk factors include prior exposure to ionizing radiation or chemotherapy (especially alkylating agents and topoisomerase II inhibitors), benzene and other industrial solvents, smoking, myelodysplastic syndromes (MDS), chronic myeloproliferative neoplasms, and inherited predisposition syndromes (e.g., Fanconi anemia, Down syndrome, RUNX1 familial platelet disorder). While most cases are sporadic, germline variants in genes like DDX41 and CEBPA are increasingly recognized. Quality of life (QoL) in AML is profoundly impacted—not only during intensive induction chemotherapy (with risks of sepsis, mucositis, prolonged hospitalization, and ICU admission) but also across survivorship phases. Fatigue, cognitive impairment ('chemo brain'), anxiety, depression, financial toxicity, and social isolation are prevalent. Long-term survivors may face infertility, secondary malignancies, cardiovascular complications, and persistent neurocognitive deficits. Supportive care—including psychosocial oncology, nutritional support, rehabilitation, and palliative integration—is integral to modern AML management. Early referral to specialized hematology centers significantly improves outcomes through risk-adapted therapy, access to clinical trials, and multidisciplinary expertise.

Acute Myeloid Leukemia (AML) is a clonal hematopoietic stem cell malignancy characterized by uncontrolled proliferation and arrested differentiation of myeloid progenitor cells in the bone marrow and peripheral blood. While the precise etiology remains incompletely understood, AML arises from acquired somatic mutations that disrupt normal regulation of self-renewal, proliferation, differentiation, and apoptosis. Unlike many solid tumors, AML is not typically attributable to a single causative agent but rather results from cumulative genetic and epigenetic alterations interacting with host and environmental susceptibilities.

Common causes include de novo genetic mutations occurring spontaneously during hematopoiesis—particularly in genes governing transcriptional regulation (e.g., RUNX1, CEBPA), signal transduction (e.g., FLT3, KIT, RAS), tumor suppression (e.g., TP53), chromatin remodeling (e.g., ASXL1, EZH2, DNMT3A), and spliceosome machinery (e.g., SF3B1, SRSF2). These mutations confer a selective growth advantage to pre-leukemic clones, which may persist for years before acquiring secondary hits that trigger overt leukemia. Therapy-related AML (t-AML), accounting for ~10–20% of cases, represents a distinct clinical and biological subtype arising as a late complication of cytotoxic chemotherapy or radiation therapy—especially alkylating agents (e.g., cyclophosphamide, melphalan) and topoisomerase II inhibitors (e.g., etoposide, doxorubicin). t-AML often carries high-risk features including complex karyotypes, TP53 mutations, and poor response to standard induction.

Triggers are not discrete external events per se but rather exposures or physiological stressors that promote genomic instability or clonal expansion in predisposed individuals. Examples include severe inflammatory states (e.g., chronic infections, autoimmune disorders), prolonged cytopenias (e.g., in myelodysplastic syndromes [MDS]), or hematopoietic stress induced by bone marrow failure syndromes. Chemotherapy-induced DNA damage can act as a mutagenic trigger, while aging-associated inflammation ('inflammaging') and declining DNA repair capacity may facilitate mutation accumulation.

Established risk factors encompass age (median diagnosis at 68 years; incidence rises exponentially after age 60), male sex (slight male predominance), and prior hematologic disorders—most notably MDS, chronic myelomonocytic leukemia (CMML), and aplastic anemia. Clonal hematopoiesis of indeterminate potential (CHIP), defined by the presence of leukemia-associated somatic mutations (e.g., DNMT3A, TET2, ASXL1) in peripheral blood without cytopenias or dysplasia, confers a 0.5–1% annual risk of progression to AML and is strongly associated with aging and cardiovascular disease.

Genetic factors include both inherited predisposition syndromes and germline variants. High-penetrance hereditary conditions include Fanconi anemia, Bloom syndrome, ataxia-telangiectasia, and constitutional mismatch repair deficiency—all involving defective DNA damage response pathways. Familial AML syndromes linked to germline mutations in CEBPA, RUNX1, GATA2, DDX41, and ANKRD26 confer lifetime AML risks ranging from 20% to >60%. Notably, germline DDX41 mutations are among the most common inherited causes of adult-onset AML/MDS. Genome-wide association studies have also identified low-penetrance polymorphisms near genes such as CDKN2A/B, IKZF1, and ARID5B that modestly modulate susceptibility.

Environmental factors are less consistently implicated than in other cancers but include prolonged high-dose benzene exposure (e.g., in shoemaking, petrochemical, or rubber industries), which induces chromosomal aberrations and oxidative DNA damage. Ionizing radiation—whether from atomic bomb exposure, therapeutic radiotherapy, or occupational settings—is a well-documented risk factor, particularly when delivered to large bone marrow volumes. Smoking tobacco increases AML risk by approximately 1.5- to 2-fold, likely via benzene metabolites and reactive oxygen species. Emerging evidence suggests obesity (BMI ≥30 kg/m²) and certain agricultural pesticides (e.g., organophosphates) may contribute modestly, though data remain inconclusive. Importantly, no credible evidence links AML to electromagnetic fields, mobile phone use, or routine diagnostic radiography. Overall, AML pathogenesis reflects a multifactorial interplay between stochastic mutagenesis, inherited genomic vulnerability, age-related clonal dynamics, and select environmental insults—underscoring the necessity of comprehensive molecular profiling and personalized risk assessment in clinical hematology.

Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy characterized by clonal proliferation and arrested differentiation of myeloid progenitor cells in the bone marrow and peripheral blood. Symptoms arise from bone marrow failure, leukemic infiltration, and systemic inflammatory effects. Early symptoms are often nonspecific and insidious, frequently mistaken for viral illness or fatigue-related conditions. Patients commonly report progressive fatigue, unexplained weakness, and diminished exercise tolerance due to anemia. Pallor, dizziness upon standing (orthostatic hypotension), and exertional dyspnea may accompany hemoglobin levels below 10 g/dL. Low-grade fever without localized signs of infection—often termed 'fever of unknown origin'—is prevalent and reflects cytokine release and impaired immune surveillance rather than overt infection. Mild, persistent arthralgias or myalgias may occur secondary to cytokine-mediated inflammation or early marrow expansion. Easy bruising, petechiae (especially on lower extremities and mucosal surfaces), and prolonged bleeding from minor cuts or gingival oozing signal thrombocytopenia; epistaxis and menorrhagia are also frequent early manifestations. Some patients experience subtle weight loss (>5% body weight over 6 months), night sweats, or low-grade fevers lasting >2 weeks—constituting B-symptoms, though less common in AML than in lymphomas.

Typical symptoms reflect overt cytopenias and organ infiltration. Profound anemia manifests as tachycardia, systolic flow murmurs, lightheadedness, and cognitive slowing. Severe thrombocytopenia (<20 × 10⁹/L) predisposes to spontaneous mucocutaneous hemorrhage, retinal hemorrhages, and, rarely, intracranial bleeding. Neutropenia (<1.0 × 10⁹/L), particularly with absolute neutrophil count <500/μL, results in recurrent or persistent bacterial and fungal infections—including pneumonia, cellulitis, perirectal abscesses, and sepsis—often with atypical pathogens (e.g., Asa, Pseudomonas). Leukostasis—a medical emergency—occurs when circulating blast counts exceed 100 × 10⁹/L, causing microvascular sludging. This presents with headache, confusion, visual disturbances (blurred vision, retinal hemorrhages), dyspnea, hypoxia, and acute respiratory distress syndrome (ARDS); neurological deficits such as aphasia or focal weakness may mimic stroke. Gingival hyperplasia—tender, swollen, friable gums—is characteristic of monocytic (M4/M5) subtypes. Skin involvement (leukemia cutis) appears as firm, violaceous, nonpruritic nodules or plaques, most commonly on the trunk, face, or extremities. Chloromas (granulocytic sarcomas) are extramedullary tumor masses that may present as orbital proptosis, epidural spinal cord compression, or intestinal obstruction.

Accompanying symptoms include constitutional manifestations: drenching night sweats, unintentional weight loss (>10% in 6 months), and profound malaise. Bone pain—particularly in the sternum, pelvis, or long bones—results from marrow expansion and periosteal stretching. Splenomegaly (often mild to moderate) may cause left upper quadrant discomfort or early satiety; hepatomegaly is less common but possible. Lymphadenopathy is uncommon in de novo AML but may occur in therapy-related or mixed-phenotype cases. Hyperleukocytosis can induce tumor lysis syndrome (TLS), presenting with acute kidney injury (oliguria, elevated creatinine), cardiac arrhythmias (due to hyperkalemia), and neuromuscular irritability (tetany from hypocalcemia). Disseminated intravascular coagulation (DIC) is a life-threatening complication, especially in acute promyelocytic leukemia (APL, FAB M3), manifesting as widespread ecchymoses, mucosal bleeding, microangiopathic hemolytic anemia, and laboratory findings of elevated D-dimer, fibrin degradation products, prolonged PT/aPTT, and low fibrinogen.

Complications extend beyond initial presentation. Infectious complications dominate morbidity and mortality: neutropenic enterocolitis (typhlitis), invasive fungal sinusitis, and catheter-related bloodstream infections are frequent. Chemotherapy-induced mucositis increases aspiration and septic risk. Differentiation syndrome—formerly retinoic acid syndrome—occurs during induction therapy for APL and presents with fever, respiratory distress, pulmonary infiltrates, pleural/pericardial effusions, hypotension, and renal impairment due to cytokine storm and capillary leak. Hemorrhagic complications include intracranial hemorrhage (especially with platelet counts <10 × 10⁹/L and coagulopathy), gastrointestinal bleeding, and post-procedural hemorrhage. Cardiac toxicity from anthracyclines (e.g., daunorubicin) may precipitate congestive heart failure. Long-term survivors face risks of therapy-related myeloid neoplasms, infertility, and secondary malignancies.

Diagnosis requires integration of clinical, morphologic, immunophenotypic, cytogenetic, and molecular data. Peripheral blood smear reveals ≥20% blasts (or any percentage if specific genetic abnormalities are present), along with cytopenias and dysplastic features. Bone marrow aspirate and biopsy are mandatory: ≥20% myeloblasts confirms AML per WHO 2022 criteria (excluding APL with PML::RARA, which is diagnostic at any blast count). Flow cytometry establishes myeloid lineage (CD13, CD33, CD117, MPO positivity) and excludes lymphoid or mixed-phenotype disease. Cytogenetics (karyotyping) identifies prognostically critical abnormalities: t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, inv(16)(p13.1q22)/CBFB::MYH11, and t(15;17)(q24.1;q21.2)/PML::RARA define favorable-risk entities; complex karyotype, monosomal karyotype, -5/del(5q), -7/del(7q), and TP53 mutations confer adverse risk. Molecular testing (PCR, NGS) detects FLT3-ITD/TKD, NPM1, CEBPA (biallelic), IDH1/2, ASXL1, RUNX1, and spliceosome mutations, refining classification and guiding targeted therapy (e.g., midostaurin for FLT3-mutated AML, ivosidenib for IDH1-mutated disease).

Differential diagnosis includes other acute leukemias: Acute Lymphoblastic Leukemia (ALL) typically affects younger patients, presents with more pronounced lymphadenopathy and CNS involvement, and shows lymphoid markers (CD19, CD22, TdT) without myeloid antigens. Chronic Myeloid Leukemia in blast crisis mimics AML but retains BCR::ABL1 fusion (detectable by PCR/FISH) and often shows basophilia and splenomegaly in chronic phase. Myelodysplastic syndromes (MDS) with excess blasts (≥20%) are reclassified as AML; however, lower-blast MDS presents with chronic cytopenias and dysplasia without overt blast proliferation. Aplastic anemia causes pancytopenia but lacks blasts and shows hypocellular marrow. Megaloblastic anemia (B12/folate deficiency) exhibits macrocytosis and hypersegmented neutrophils but no blasts. Infectious mononucleosis and HIV-associated cytopenias may show atypical lymphocytes but lack myeloid blasts. Reactive leukemoid reactions demonstrate extreme leukocytosis with mature granulocytes and toxic granulation, normal or elevated leukocyte alkaline phosphatase (LAP), and absence of cytogenetic/molecular AML markers. Accurate distinction mandates comprehensive laboratory evaluation to avoid misclassification and ensure appropriate risk-adapted therapy.

Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy characterized by uncontrolled proliferation and impaired differentiation of myeloid progenitor cells in the bone marrow and peripheral blood. Management requires rapid diagnosis, risk stratification, and multidisciplinary intervention led by hematology-oncology specialists. Treatment is broadly divided into induction, consolidation, and maintenance or targeted therapy phases, with decisions guided by age, performance status, cytogenetic and molecular profile (e.g., FLT3-ITD, NPM1, TP53, IDH1/2 mutations), and comorbidities.

Conservative treatment plays a critical supportive role throughout AML management but is not curative as monotherapy. It encompasses rigorous infection prophylaxis (e.g., fluoroquinolone or antifungal agents in neutropenic patients), transfusion support (leukoreduced red blood cells for hemoglobin <7–8 g/dL; platelet transfusions for counts <10 × 10⁹/L or active bleeding), tumor lysis syndrome (TLS) prevention (aggressive hydration, rasburicase or allopurinol, close electrolyte monitoring), and growth factor use—though granulocyte colony-stimulating factor (G-CSF) is generally avoided during induction due to theoretical concerns about leukemic blast proliferation. Nutritional support, psychological counseling, and symptom-directed palliative care are integral, especially for older adults or those unfit for intensive chemotherapy. For patients with contraindications to standard induction (e.g., severe cardiac, pulmonary, or hepatic dysfunction), low-intensity regimens such as azacitidine + venetoclax may serve as a bridge to supportive care or clinical trial enrollment.

Medication remains the cornerstone of AML therapy. Standard induction for fit patients (<60–65 years, good organ function) consists of '7+3' chemotherapy: cytarabine 100–200 mg/m² IV continuously for 7 days plus an anthracycline (idarubicin 12 mg/m² or daunorubicin 60–90 mg/m² IV on days 1–3). This achieves complete remission (CR) in ~60–80% of younger adults. Consolidation involves high-dose cytarabine (HiDAC; 3 g/m² IV every 12 hours on days 1, 3, and 5 for 2–4 cycles), which improves disease-free survival, particularly in favorable- and intermediate-risk groups. For adverse-risk AML—including complex karyotype, TP53 mutation, or therapy-related disease—allogeneic hematopoietic stem cell transplantation (allo-HSCT) is strongly recommended in first CR. Targeted agents have transformed precision management: FLT3 inhibitors (midostaurin, gilteritinib, quizartinib) are now standard-of-care—midostaurin combined with 7+3 improves overall survival in newly diagnosed FLT3-mutated AML, while gilteritinib is approved for relapsed/refractory FLT3-mutated disease. IDH1/2 inhibitors (ivosidenib, enasidenib) demonstrate durable responses in IDH-mutant AML, including in elderly or unfit patients. Venetoclax, a BCL-2 inhibitor, combined with hypomethylating agents (azacitidine or decitabine) or low-dose cytarabine, has become the preferred frontline regimen for patients ≥75 years or those with significant comorbidities, yielding CR rates of 60–70% and median overall survival exceeding 14 months. Other agents under investigation include menin inhibitors (e.g., revumenib) for KMT2A-rearranged or NPM1-mutant AML, and antibody-drug conjugates (e.g., vadastuximab talirine, though withdrawn due to toxicity, informs ongoing development).

Surgical treatment has no primary role in AML pathophysiology, as it is a systemic hematologic disorder without localized resectable mass. However, minor surgical procedures are routinely employed: bone marrow biopsy and aspiration (often bilateral iliac crest) for diagnosis, response assessment, and minimal residual disease (MRD) monitoring; central venous catheter placement (e.g., tunneled Hickman or PICC line) for safe administration of chemotherapy, transfusions, and parenteral nutrition; and occasionally lumbar puncture with intrathecal chemotherapy (e.g., cytarabine or methotrexate) in cases with suspected or confirmed central nervous system involvement—though CNS relapse is rare in AML (<5%). Allo-HSCT, while often categorized under medical oncology, involves procedural elements including stem cell harvest (from donor peripheral blood or bone marrow) and conditioning regimens (myeloablative or reduced-intensity), followed by infusion and post-transplant immune reconstitution management.

China offers distinct advantages in AML treatment delivery. First, the national healthcare system enables rapid access to standardized diagnostic workflows—including next-generation sequencing (NGS) panels for >50 AML-relevant genes—widely available at Tier-3 hospitals in Beijing, Shanghai, Guangzhou, and Chengdu, often within 5–7 working days. Second, China hosts one of the world’s largest repositories of real-world AML data, facilitating robust clinical research and regulatory approvals: the NMPA has granted priority review and accelerated approval for gilteritinib, ivosidenib, and venetoclax based on local phase II/III trials demonstrating efficacy comparable to global cohorts. Third, cost-effectiveness is notable—generic formulations of cytarabine, daunorubicin, and azacitidine are widely accessible, and biosimilar G-CSF reduces supportive care expenses. Fourth, China leads in allo-HSCT infrastructure: over 120 accredited transplant centers perform >10,000 transplants annually, with high donor availability via the China Marrow Donor Program (CMDP), now the world’s second-largest registry (>3.5 million donors). Finally, integrated traditional Chinese medicine (TCM) adjuncts—such as compound Kushen injection or Astragalus polysaccharide—are evidence-informed adjuvants used to mitigate chemotherapy-induced myelosuppression and improve quality of life, supported by randomized controlled trials published in journals like *Leukemia Research* and *Annals of Hematology*.

Recovery advice emphasizes longitudinal, patient-centered care. Patients should adhere strictly to scheduled follow-up visits (every 1–3 months for first year post-remission), including peripheral blood counts, bone marrow examinations, and MRD assessment via multiparameter flow cytometry or NGS-based assays. Vaccination status must be reviewed and updated post-chemotherapy or transplant (avoiding live vaccines for ≥24 months after allo-HSCT). Lifestyle modifications include strict hand hygiene, avoidance of raw seafood/unpasteurized dairy, and prompt reporting of fever (>38.0°C), bruising, or dyspnea. Nutritional guidance prioritizes high-protein, low-microbial-risk diets; physical rehabilitation (graded aerobic and resistance training) mitigates cancer-related fatigue and sarcopenia. Psychosocial support—including peer mentoring through organizations like the China Leukemia Foundation—and fertility preservation counseling (especially before alkylator-based conditioning) are essential components. Long-term survivors require surveillance for late effects: secondary malignancies, endocrine dysfunction (e.g., thyroid, gonadal), cardiovascular disease, and chronic graft-versus-host disease (cGVHD) in transplant recipients. With evolving therapeutic paradigms, 5-year overall survival now exceeds 65% for favorable-risk younger adults and approaches 35–45% for older patients receiving venetoclax-based regimens—underscoring the importance of timely referral to specialized hematology centers.